The use of health economic evaluations in pharmaceutical priority setting - The case of Sweden
The production of health economic evaluations of pharmaceuticals is a global, multibillion dollar industry. Despite this fact, little is known about what happens after a health economic evaluation has been produced. Will it be used at all, and if so, how? Who uses economic evaluations and for what purposes? Are there differences in the use patterns between decision makers at macro, meso and micro
